Leerink Partnrs Comments on Sage Therapeutics, Inc.'s Q3 2023 Earnings (NASDAQ:SAGE)

Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report) – Equities researchers at Leerink Partnrs decreased their Q3 2023 earnings per share (EPS) estimates for shares of Sage Therapeutics in a research note issued to investors on Monday, August 7th. Leerink Partnrs analyst M. Goodman now anticipates that the biopharmaceutical company will earn ($2.59) per share for […]

Related Keywords

,Leerink Partnrs ,Canaccord Genuity Group ,Sage Therapeutics Inc ,Metlife Investment Management ,Nasdaq ,Tower Research Capital ,Scotiabank ,Headlands Technologies ,Hanseatic Management Services Inc ,Sage Therapeutics ,Free Report ,Sage Therapeutic ,Get Free Report ,Management Services ,Life Investment Management ,Research Capital ,Dark Forest Capital Management ,Sage Therapeutics Daily ,Nasdaq Sage ,Sage ,Medical ,Earnings Estimates ,